Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4305-4319

  Pastò, Anna ^a   Bellio, Chiara ^a   Pilotto, Giorgia ^a   Ciminale, Vincenzo ^a,b   Silic Benussi, Micol ^b   Guzzo, Giulia ^a   Rasola, Andrea ^a   Frasson, Chiara ^a   Nardo, Giorgia ^b   Zulato, Elisabetta ^b   Nicoletto, Maria Ornella ^b   Manicone, Mariangela ^b   Indraccolo, Stefano ^b   Amadori, Alberto ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer stem cells; Glucose; Metabolism; Ovarian cancer; Warburg effect

Indexed keywords

6 PHOSPHOFRUCTOKINASE; CITRATE SYNTHASE; CITRININ; CYTOKERATIN 7; DEOXYGLUCOSE; DOXORUBICIN; FATTY ACID; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; HERMES ANTIGEN; HEXOKINASE; HEXOKINASE ISOENZYME; ISOCITRATE DEHYDROGENASE; METFORMIN; MONOCARBOXYLATE TRANSPORTER 4; OLIGOMYCIN; PENTOSE PHOSPHATE; PRASTERONE; PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; RIBULOSE PHOSPHATE; ROTENONE; STEM CELL FACTOR RECEPTOR; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER INHIBITION; CANCER PATIENT; CANCER STEM CELL; CD44+ CD117+ CELL; CELL VIABILITY; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GLUCOSE DEPRIVATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; PROTEIN EXPRESSION; RESPIRATORY CHAIN; UPREGULATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; GENETICS; METABOLISM; NEOPLASM; OVARY TUMOR; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLUCOSE; HUMANS; MICROSCOPY, CONFOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; OXIDATIVE PHOSPHORYLATION;

EID: 84905118703     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2010     Document Type: Article

References (46)

1. Koppenol WH, Bounds PL and Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11(5):325-337.
2. Magee JA, Piskounova E and Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21(3):283-296.
3. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP and Pelicci PG. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 2009; 138(6):1083-1095.
4. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T and Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010; 141(4):583-594.
5. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17(3):313-319.
6. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, Reue K, Christofk H, Mischel PS and Pajonk F. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011; 108(38):16062-16067.
7. Kipps E, Tan DS and Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013; 13(4):273-282.
8. Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 2013; 104(3):275-281.
9. Ward PS and Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308.
10. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-4320.
11. Bapat SA, Mali AM, Koppikar CB and Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005; 65(8):3025-3029.
12. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T and Mor G. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 2013; 32(1):39-49.
13. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY and Bapat SA. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009; 27(9):2059-2068.
14. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I and Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009; 8(1):158-166.
15. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS and Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009; 69(8):3382-3389.
16. Wieman HL, Horn SR, Jacobs SR, Altman BJ, Kornbluth S and Rathmell JC. An essential role for the Glut1 PDZ-binding motif in growth factor regulation of Glut1 degradation and trafficking. Biochem J. 2009; 418(2):345-367.
17. Jimenez PT, Frolova AI, Chi MM, Grindler NM, Willcockson AR, Reynolds KA, Zhao Q and Moley KH. DHEA-Mediated Inhibition of the Pentose Phosphate Pathway Alters Oocyte Lipid Metabolism in Mice. Endocrinology. 2013; 154(12):4835-4844.
18. Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, Kim YM, Lomenick B, Okemoto K, Landaw EM, Wang D, Mazitschek R, Bradner JE and Sakamoto KM. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma. 2011; 52(8):1544-1555.
19. Pike LS, Smift AL, Croteau NJ, Ferrick DA and Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta. 2011; 1807(6):726-734.
20. Roche TE, Baker JC, Yan X, Hiromasa Y, Gong X, Peng T, Dong J, Turkan A and Kasten SA. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog Nucleic Acid Res Mol Biol. 2001; 70:33-75.
21. Wong N, De Melo J and Tang D. PKM2, a Central Point of Regulation in Cancer Metabolism. Int J Cell Biol. 2013; 2013:242513.
22. Chen M, Zhang J and Manley JL. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 2010; 70(22):8977-8980.
23. Pendergrass W, Wolf N and Poot M. Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry A. 2004; 61(2):162-169.
24. Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Megighian A, Merlini L, Braghetta P, Columbaro M, Volpin D, Bressan GM, Bernardi P and Bonaldo P. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet. 2003; 35(4):367-371.
25. Nicholls DG and Ward MW. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci. 2000; 23(4):166-174.
26. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275(1):223-228.
27. Nardo G, Favaro E, Curtarello M, Moserle L, Zulato E, Persano L, Rossi E, Esposito G, Crescenzi M, Casanovas O, Sattler U, Mueller-Klieser W, Biesalski B, Thews O, Canese R, Iorio E, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res. 2011; 71(12):4214-4225.
28. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012; 109(8):2784-2789.
29. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nistér M, Reifenberger G, Lundeberg J, Frisén J and Acker T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010; 133(Pt 4):983-995.
30. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, Schwartz L and Icard P. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res. 2006; 26(5A):3561-3566.
31. Pastò A, Marchesi M, Diamantini A, Frasson C, Curtarello M, Lago C, Pilotto G, Parenti AR, Esposito G, Agostini M, Nitti D and Amadori A. PKH26 staining defines distinct subsets of normal human colon epithelial cells at different maturation stages. PLoS One. 2012; 7(8):e43379.
32. Zeuner A and De Maria R. Not so lonely at the top for cancer stem cells. Cell Stem Cell. 2011; 9(4):289-290.
33. Leontieva OV and Blagosklonny MV. (2014). M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.
34. Menendez JA, Alarcon T and Joven J. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. Cell Cycle. 2014; 13(5):699-709.
35. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013; 155(7):1624-1638.
36. Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008; 452(7184):181-186.
37. Luo W and Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012; 23(11):560-566.
38. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-233.
39. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN and Hjelmeland AB. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013; 16(10):1373-1382.
40. Rasola A and Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium. 2011; 50(3):222-233.
41. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H and AndreeffM. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest. 2010; 120(1):142-156.
42. Zulato E, Curtarello M, Nardo G and Indraccolo S. Metabolic effects of anti-angiogenic therapy in tumors. Biochimie. 2012; 94(4):925-931.
43. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB and Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009; 8(20):3274-3284.
44. Lonardo E, CioffiM, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M and Heeschen C. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One. 2013; 8(10):e76518.
45. Silic-Benussi M, Cavallari I, Vajente N, Vidali S, Chieco-Bianchi L, Di Lisa F, Saggioro D, D'Agostino DM and Ciminale V. Redox regulation of T-cell turnover by the p13 protein of human T-cell leukemia virus type 1: distinct effects in primary versus transformed cells. Blood. 2010; 116(1):54-62.
46. Lin RJ, Sternsdorf T, Tini M and Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene. 2001; 20(49):7204-7215.